Susceptibility of Vibrio cholerae O139 to antibody-dependent, complement-mediated bacteriolysis.
Volunteer studies with Vibrio cholerae O1 have shown that the best correlate of a vaccine's protective efficacy is its propensity to elicit serum bactericidal responses in its recipients. Attempts to detect such responses following infection with V. cholerae O139, however, have met with varying success. Using a tube-based assay which involves viable counting, we now report that strains of serogroup O139 can appear to be sensitive or resistant to a fixed concentration of complement in the presence of antibody, depending on assay conditions. Susceptibility to lysis is critically dependent on the availability of complement, but with O139 indicator strains this is not simply determined by the concentration of serum added to the reaction mix. The nature of the assay diluent and the concentration of indicator bacteria can also dramatically affect bactericidal end points, whereas such variables have minimal significance with O1 indicator bacteria. Although some laboratories use unencapsulated mutant strains to seek evidence of seroconversion following exposure to V. cholerae O139, this is not necessary, and our findings question the significance of capsule expression as a determinant of complement sensitivity when antibody is present. The medium used for growth of the indicator strain and the particular strain used appeared to be unimportant. Each of seven O139 isolates tested was found to be lysed by antibody and complement in our standard assay system, which allowed the detection of significant serum bactericidal responses in 9 of 11 cases of O139 disease.
Attridge
S R
SR
Microbial Pathogenesis Unit, Department of Microbiology and Immunology, The University of Adelaide, South Australia 5005, Australia. stephen.attridge@adelaide.edu.au
Qadri
F
F
Albert
M J
MJ
Manning
P A
PA
D000907:Antibodies, Bacterial / Q000276:immunology; D000911:Antibodies, Monoclonal; D016667:Bacterial Capsules / Q000276:immunology; D001770:Blood Bactericidal Activity; D002771:Cholera / Q000175:diagnosis* / Q000276:immunology; D003167:Complement Activation / Q000276:immunology*; D015941:Complement Hemolytic Activity Assay; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D007201:Indicator Dilution Techniques; D014734:Vibrio cholerae / Q000276:immunology* / Q000302:isolation & purification*
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007075:Immunoglobulin M